To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: [18F]AZD4694

Study type: Interventional

Funder types: Industry

Identifiers

NCT00991419

D2750N00006

Details and patient eligibility

About

The purpose of this study is to compare PET measurements of fibrillar amyloid burden using [18F]AZD4694.

Enrollment: 25 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male or female, of any race or/ethnicity
• ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician

Exclusion criteria

• Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse
• Participated in a PET study within the last 12 months
• Pregnancy or lactation

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

A

Experimental group

Description:

\[18F\]4694

Treatment:

Drug: [18F]AZD4694